Table 5.5.

Mismatch related marrow or matched unrelated donor transplantation for patients with thalassemia major

Refs.	Transplant regimen	Graft type	Pesaro Class	No. of patients (age)	Alive without TM	Acute GvHD (Gr 2–4)	Chronic GvHD (extensive)	Death
Sullivan et al. [63]	Bu, Cy, MTX, CSA	Unrelated	Class 2 and 3	4(1–16)	2	NR	NR	1
La Nasa et al. [68, 69]	Bu 14 mg/kg, Cy 200 mg/kg, TT 10 mg/kg, ATG, CSA, MTX,	Unrelated BM, 10 of 10 match 85%	Class 1, 14	68(2–37)	Class 1+2: 24(80%)	24(35%, gr 2–4)	5	16(most were in class 3)
			Class 2, 16		Class 3: 21(55%)
			Class 3, 38
Feng et al. [93]	Bu 16 mg/kg, Cy 200 mg/kg, ALG	Unrelated, BM, includes 1 and 2 alleles mismatch	Class 1,3	9(1–9)	7(78%)	6	1	1
			Class 2, 4
			Class 3, 2
Resnick et al. [94]	Bu 16 mg/kg, Flu 180 mg/kg, ATG	Unrelated, 1 BM, 1 PBSC	Both Class 1	2(2 and 4)	1	NR	NR	NR
Li et al. [70]	Bu 12–13.2 mg/kg, Cy 100–120 mg/kg, TT 5 mg/kg, Flu 160 mg/m2, ATG, MTX, CSA, MMF	Unrelated, PBSC 8/8: 32, 7/8: 19, 6/8: 1	Class 1,9	52(2–15)	50(96%)	4(8%, grade 3–4)	0	4, 2 directly from GvHD
			Class 2, 82
			Class 3,9
Total	Backbone of Bu, Cy, ATG			135	105(78%)	26%(of total)	5%(of total)	17%(of total)
						33%(of engrafted)	6%(of engrafted)

Abbreviations: SCD sickle cell disease, GvHD graft-versus-host disease, Bu busulfan, Cy cyclophosphamide, ATG anti-thymocyte globulin, CSA cyclosporine A, MTX methotrexate, Flu fiudarabine, Mel melphalan, MMF mycophenolate mofetil, ALG TT thiotepa, Gr grade, NR not reported, Gy gray